The role of resveratrol for preventing the ovarian hyperstimulation syndrome

Prospective, double-blinded, randomized clinical trial to evaluate the potential benefitial effect of resveratrol for preventing the ovarian hyperstimulation syndrome. - The role of resveratrol for preventing the ovarian hyperstimulation syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-003986-11-ES

Enrollment

Registered

2015-04-27

Start date

2016-10-22

Completion date

Unknown

Last updated

2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resveratrol may prevent the incidence of ovarian hyperstimulation syndrome by reducing the expression of VEGF and estradiol, improving the haemoconcentration and ascitis Re

Interventions

Trade Name: Resveratrol Product Name: Resveratrol Pharmaceutical Form: Capsule Pharmaceutical form of the placebo: Capsule Route of admi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Egg donors who meet the following criteria: 1. Number of follicles (>12 mm) > o = 21 in the last scan previous ovum pick-up. 2. Number of retrieved oocytes > o =21. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 70 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Exclusión criteria for egg donation: >35 years, polycystic ovary syndrome, endometriosis, severe systematic pathology, positive serologies for BHV, CHV o HIV, or altered karyotype.

Design outcomes

Primary

Measure	Time frame
Main Objective: Evaluate the effect of resveratrol on VEGF levels;Secondary Objective: Evaluate the effect of resveratrol on haemoconcentration, estradiol levels and ascitis;Primary end point(s): Levels of VEGF;Timepoint(s) of evaluation of this end point: 3, 6 and 9 days after ovulation triggering with GnRH agonist	—

Secondary

Measure	Time frame
Secondary end point(s): Haemococentration, estradiol levels, levels of ascitic fluid, laboratory parameters;Timepoint(s) of evaluation of this end point: 3, 6 and 9 days after ovulation triggering with GnRH agonist	—

Countries

Spain

Contacts

Public ContactIsrael Ortega

IVI Madrid

Israel.Ortega@ivi.es0034911802900

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026